MPN-541 Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera With the Hepcidin Mimetic, Rusfertide: Blinded Randomized Withdrawal Results of the Phase 2 Revive Study

Polycythemia vera (PV) is a clonal myeloproliferative neoplasm characterized by uncontrolled erythrocytosis, systemic symptoms, and an increased risk of thromboembolic (TE) and cardiovascular (CV) complications. The REVIVE study (PTG-300-04; NCT04057040) investigated the effect of rusfertide, a firs...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2023-09, Vol.23, p.S400-S401
Main Authors: Pemmaraju, Naveen, Kremyanskaya, Marina, Kuykendall, Andrew, Ritchie, Ellen, Gotlib, Jason, Gerds, Aaron, Palmer, Jeanne, Pettit, Kristen, Nath, Uttam, Yacoub, Abdulraheem, Molina, Arturo, Modi, Nishit, Valone, Frank, Khanna, Sarita, Gupta, Suneel, Verstovsek, Srdan, Ginzburg, Yelena, Hoffman, Ronald
Format: Article
Language:English
Subjects:
erythrocytosis
hepcidin mimetic
MPN
polycythemia vera
rusfertide
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Polycythemia vera (PV) is a clonal myeloproliferative neoplasm characterized by uncontrolled erythrocytosis, systemic symptoms, and an increased risk of thromboembolic (TE) and cardiovascular (CV) complications. The REVIVE study (PTG-300-04; NCT04057040) investigated the effect of rusfertide, a first-inclass hepcidin mimetic, in controlling erythrocytosis in patients with PV. We report results from the randomized withdrawal phase of the study. The REVIVE trial consists of three stages. During Part 1 (28 wk), rusfertide dose was adjusted individually to control HCT
ISSN:2152-2650
2152-2669
DOI:10.1016/S2152-2650(23)01253-3